Tectonic Advisors LLC Has $539,000 Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Tectonic Advisors LLC increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 12.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,374 shares of the specialty pharmaceutical company’s stock after purchasing an additional 483 shares during the period. Tectonic Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $539,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. CWA Asset Management Group LLC bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Centre Asset Management LLC bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth approximately $9,335,000. Pacer Advisors Inc. grew its holdings in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Jazz Pharmaceuticals by 4.6% in the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after purchasing an additional 48,708 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Robert W. Baird upped their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. TD Cowen decreased their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Piper Sandler restated an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.00.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 8,753 shares of company stock valued at $1,074,059. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.1 %

JAZZ opened at $121.53 on Thursday. The company has a market capitalization of $7.35 billion, a P/E ratio of 17.12, a P/E/G ratio of 0.90 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm’s fifty day moving average price is $122.60 and its two-hundred day moving average price is $116.32. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.